Asthma
Conditions
Keywords
asthma, control rate, budesonide/formoterol, Non-Interventional study
Brief summary
This is a multi-centre, cross-sectional study planned to be conducted in China. The study aims to observe about 1500 asthma patients who have already received budesonide/formoterol combination treatment by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China.
Detailed description
The asthma control rate achieved by budesonide/formoterol in clinical practice in China.
Interventions
OTHERwithout interventions
without interventions
Sponsors
AstraZeneca
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Clinical diagnosis of asthma at least 6 months; 2. Prescribed with budesonide/formoterol treatment at least 3 months before enrolled; 3. Has used the same maintenance dose of budesonide/formoterol for at least 4 weeks before enrolled.
Exclusion criteria
1. Participation in any clinical study within 3 months; 2. Have COPD history/suspicious COPD; 3. ≥ 10 pack years of smoking history 4. Used any other asthma maintenance medication accompanied with budesonide/formoterol within 3 months before enrolled 5. With asthma exacerbation (defined as asthma symptom deterioration resulting oral/rectal/parenteral GCS medication or emergency room treatment or hospitalisation) within 4 weeks before enrolled
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of controlled and partly controlled asthma according to the definition of Global Initiative for Asthma | one day |
Secondary
| Measure | Time frame |
|---|---|
| The rate of completely controlled and well controlled asthma according to Asthma Control Test's score | one day |
| The average frequency of reliever use in previous week | one day |
Countries
China
Outcome results
None listed